Article Sidebar
Published:
Sep 6, 2024DOI:
10.4314/tjpr.v23i7.3Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Dexamethasone-triggered hepatic and renal impairment in albino rats, and its amelioration through royal jelly intervention
Abstract
Purpose: To evaluate the hepato-renal protective effect of royal jelly (RJ) against dexamethasone (DEX)-induced toxicity in rat models.
Methods: Twenty-four male albino Wistar rats (divided equally into three groups) were administered DEX with or without RJ while control group received normal saline. The serum levels of aspartate aminotransferase (AST), alanine aminotransaminase (ALT), creatinine, uric acid, albumin, and hepatic activities of glucose-6-phosphate dehydrogenase (G6PD) and catalase, as well as levels of glutathione (GSH) and total protein, were measured. Body, kidney and liver weights, as well as blood glucose concentrations, were measured, before and after treatment.
Results: Dexamethasone (DEX) produced significant hyperglycemia and hyperuricemia and significant increases in concentrations of kidney and liver function biomarkers (p < 0.05). These changes were accompanied by decreased liver levels of GSH, total protein and catalase. These alterations were significantly reversed in DEX-treated rats given RJ, compared to rats receiving only DEX (p < 0.05). Body weights were also significantly augmented in DEX-injected rats given RJ, relative to rats given DEX alone (p < 0.05).
Conclusion: Royal jelly significantly reduces DEX-induced renal and hepatic toxicities, which suggests its probable therapeutic significance in inhibiting glucocorticoid-mediated adverse reactions. This phenomenon should be further investigated and the possible mechanism elucidated.
